Page last updated: 2024-09-04

canertinib and Astrocytoma, Grade IV

canertinib has been researched along with Astrocytoma, Grade IV in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Appleman, VA; Charest, A; Jun, HJ; Sarkaria, JN; Varma, H; Yeo, AT; Zhang, P	1

Other Studies

1 other study(ies) available for canertinib and Astrocytoma, Grade IV

Article	Year
EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma. Oncogene, 2021, Volume: 40, Issue:15 Topics: Animals; Apoptosis; Brain Neoplasms; ErbB Receptors; Glioblastoma; HEK293 Cells; Heterografts; Humans; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Receptor, Platelet-Derived Growth Factor alpha	2021

Article

Year

EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma.

Oncogene, 2021, Volume: 40, Issue:15

Topics: Animals; Apoptosis; Brain Neoplasms; ErbB Receptors; Glioblastoma; HEK293 Cells; Heterografts; Humans; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Receptor, Platelet-Derived Growth Factor alpha

2021